UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 13, 2021
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File
Number)
|
(IRS Employer
Identification No.)
|
|
|
||
|
(Address of Principal Executive Offices) (Zip Code)
|
||
|
(
|
||
|
(Registrant’s telephone number, including area code)
|
||
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 – Results of Operations and Financial Condition.
On July 13, 2021, AngioDynamics, Inc. (“AngioDynamics”) issued a press release announcing financial results for the fiscal fourth
quarter and full year ended May 31, 2021. A copy of the press release is furnished herewith as Exhibit 99.1.
The information set forth in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section. Furthermore, such information shall not be deemed to be incorporated by reference into any filing under the Securities
Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 7.01 – Regulation FD Disclosure.
Presentation slides discussing AngioDynamics and its fiscal fourth quarter and full year ended May 31, 2021 are furnished herewith as
Exhibit 99.2.
The presentation slides furnished pursuant to Item 7.01 of this Form 8-K (including Exhibit 99.2) shall not be deemed “filed” for
purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section. Furthermore, the presentation slides shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange
Act.
Forward-Looking Statements
This document and its attachments contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and
objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “project”, “optimistic,” or variations of such words and
similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially
from AngioDynamics’ expectations, express or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its
existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics’ technology or assertions that AngioDynamics’ technology infringes the technology of third parties, the ability of AngioDynamics to
effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical
trials, overall economic conditions, the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product
liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate
fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but
not limited to its Annual Report on Form 10-K for the year ended May 31, 2020 and its Quarterly Reports on Form 10-Q for the fiscal periods ended August 31, 2020 and November 30, 2020. AngioDynamics does not assume any obligation to publicly update
or revise any forward-looking statements for any reason.
Item 9.01 – Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No.
|
Description
|
|
|
Press Release, dated July 13, 2021.
|
||
|
Presentation, dated July 13, 2021.
|
||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
| ANGIODYNAMICS, INC. |
|||
| (Registrant) |
|||
|
Date: July 13, 2021
|
By:
|
/s/ Richard C. Rosenzweig |
|
| Name: Richard C. Rosenzweig |
|||
|
Title: Senior Vice President, General Counsel and
Secretary
|
|||
Exhibit 99.1
PRESS RELEASE
Investor Contact:
AngioDynamics, Inc.
Stephen Trowbridge, Executive Vice President & CFO
(518) 795-1408
AngioDynamics Reports Fiscal 2021 Fourth Quarter and Full-Year Financial Results
Fiscal 2021 Fourth Quarter Highlights
|
•
|
Net sales of $76.8 million increased 31.7% compared to the prior-year quarter
|
|
•
|
Gross margin of 55.1% increased 330 basis points year over year
|
|
•
|
GAAP loss per share of $0.51, inclusive of a $14.0 million write-off of OARTrac intangible
assets, and adjusted earnings per share of $0.00
|
|
•
|
Cash and cash equivalents on May 31, 2021 were $48.2 million
|
|
•
|
Received 510(k) clearance for AlphaVac Mechanical Thrombectomy System subsequent to quarter end
|
|
•
|
Received FDA approval for NanoKnife prostate IDE (PRESERVE) subsequent to quarter end
|
Full-Year 2021 Highlights
|
•
|
Net sales of $291.0 million increased 10.2% year over year
|
|
•
|
Gross margin declined 300 basis points year over year to 53.9%
|
|
•
|
GAAP loss per share of $0.82 and adjusted earnings per share of $0.05
|
Latham, New York, July 13, 2021 – AngioDynamics, Inc. (NASDAQ: ANGO), a leading
provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced financial results for the fourth quarter and fiscal year 2021, which ended May 31, 2021.
“The AngioDynamics team demonstrated excellent performance, resilience, and strong execution in what was a uniquely challenging
year. We saw the pressure from COVID-19 gradually alleviate over the course of the year, and our business is now trending close to
normalized run rates. During fiscal 2021, we took significant steps forward in our transformation into a growth-oriented,
technology-driven company, building on the foundation we put in place over the past several years,” commented Jim Clemmer, President and Chief Executive Officer of AngioDynamics, Inc. “Our investments in our key technology platforms are driving our
growth, as evidenced by a strong first-year contribution from Auryon and continued strength from AngioVac. I am excited about the future of AngioDynamics as we continue to develop differentiated products like AlphaVac, which we anticipate launching
later this year, to serve larger and faster growing markets, pursue regulatory milestones and expand our patient base.”
Fourth Quarter 2021 Financial Results
Net sales for the fourth quarter of fiscal 2021 were $76.8 million, an increase of 31.7% compared to the prior-year quarter. All
year-over-year comparisons have been affected by the disruption to procedure volumes resulting from the COVID-19 global pandemic.
Foreign currency translation did not have a significant
impact on the Company's sales in the quarter.
• Endovascular Therapies (formerly Vascular Interventions and Therapies) net sales were $38.1 million, an increase of 72.3%, compared to $22.1 million a year ago. Growth
was driven by broad strength across the business relative to the prior-year period, led by sales of the Auryon and AngioVac platforms. Auryon sales during the quarter were $4.6 million.
• Oncology net sales were $14.3 million, an increase of 14.2%, compared to $12.5 million in the prior-year period. The year-over-year growth was primarily due to
increased sales of NanoKnife and Microwave disposables and sales of the BioSentry Tract Sealant System, partially offset by continued softness in capital spending and our international markets.
• Vascular Access net sales were $24.5 million, an increase of 3.2%, compared to $23.7 million a year ago.
U.S. net sales in the fourth quarter of fiscal 2021 were $63.6 million, an increase of 42.6% from $44.6 million a year ago.
International net sales were $13.2 million, a decrease of 3.6%, compared to $13.7 million a year ago.
Gross margin for the fourth quarter of fiscal 2021 was 55.1%, an increase of 330 basis points compared to the fourth quarter of
fiscal 2020, primarily due to a reduction in COVID-related costs. During the quarter, gross margin was negatively impacted by macro forces including labor shortages and increased costs for labor, raw materials, and freight. Gross margins also continued
to be impacted by Auryon startup costs. During the fourth quarter, inventory was reduced by $0.4 million when compared to inventory
levels on February 28, 2021. During the fiscal year, inventory levels have been reduced by $11.3 million.
The Company recorded a net loss of $19.5 million, or a loss per share of $0.51, in the fourth quarter of fiscal 2021. This
compares to a net loss of $157.0 million, or a loss per share of $4.13, a year ago. The current-year net loss includes a $14.0 million write-off of the OARTrac intangible assets, while the prior-year net loss includes a goodwill impairment charge of
$158.6 million.
Excluding the items shown in the non-GAAP reconciliation table below, adjusted net loss for the fourth quarter of fiscal 2021 was
$0.1 million, and adjusted earnings per share was $0.00, compared to adjusted net loss in the prior-year period of $2.1 million and adjusted loss per share of $0.06.
Adjusted EBITDA in the fourth quarter of fiscal 2021, excluding the items shown in the reconciliation table below, was $4.5
million, compared to $0.6 million in the fourth quarter of fiscal 2020.
In the fourth quarter of fiscal 2021, the Company generated free cash flow of $3.1 million. As of May 31, 2021, the Company had
$48.2 million in cash and cash equivalents compared to $54.5 million in cash and cash equivalents on February 28, 2021. The Company reduced its debt outstanding under its revolving credit facility at May 31, 2021, to $20.0 million compared to $30.0
million on February 28, 2021.
Full-Year 2021 Financial Results
For the twelve months ended May 31, 2021:
|
•
|
Net sales were $291.0 million, an increase of 10.2%, compared to $264.2 million for the same period a year ago.
|
|
•
|
The Company's net loss from continuing operations was $31.5
million, or a loss per share of $0.82, compared to a net loss of $166.8 million, or a loss of $4.39 per share, a year ago. The current-year
net loss includes a $14.0 million write-off of the OARTrac intangible assets, while the prior-year net loss includes a goodwill impairment charge of $158.6 million.
|
|
•
|
Gross margin declined 300 basis points to 53.9% from 56.9% a
year ago due to the Company's COVID-related operating plan and increased labor, material, and freight costs, as well as Auryon start-up costs.
|
|
•
|
Excluding the items shown in the non-GAAP reconciliation table
below, adjusted net income was $1.9 million, with adjusted earnings per share of $0.05 per share, compared to adjusted net income and adjusted earnings per share of $3.5 million, or $0.09 per share, a year ago. Adjusted net income and adjusted earnings per share in
|
|
•
|
fiscal 2021 includes a $1.9 million, and $0.04 per share benefit, respectively, related to the reimbursement of certain expenses under
the CARES Act.
|
|
•
|
Adjusted EBITDA, excluding the items shown in the reconciliation table below, was $19.5 million, compared to $18.0 million for the same
period a year ago.
|
Fiscal Year 2022 Financial Guidance
The Company expects its fiscal year 2022 net sales to be
in the range of $305 to $310 million, gross margin to be approximately 55.0% and adjusted earnings per share in the range of $0.00 to $0.05 as
the Company continues to invest in new product launches to drive future growth.
Conference Call
The Company's management will host a conference call today at 8:00 a.m. ET to discuss its fourth quarter
and fiscal year 2021 results.
To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international) and refer to the passcode
13720741.
This conference call will also be webcast and can be
accessed from the “Investors” section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site
approximately one hour after the end of the call.
A recording of the call will also be available from 11:00 a.m. ET on Tuesday, July 13, 2021, until 11:59 p.m. ET on Tuesday, July
20, 2021. To hear this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13720741.
As a reminder, the Company will also be hosting its
Investor and Technology Day beginning at 9:30 a.m. ET this morning. Additional information and registration instructions can be found on the “Investors” section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the event will be archived on the same site.
Use of Non-GAAP Measures
Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in
analyzing the underlying trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this
news release, AngioDynamics has
reported adjusted EBITDA, adjusted net income, adjusted earnings per share, and free cash flow. Management uses these measures in
its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management
believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance
taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures
prepared in accordance with GAAP.
About AngioDynamics, Inc.
AngioDynamics, Inc. is a leading provider of innovative,
minimally invasive medical devices used by professional healthcare providers for vascular access, peripheral vascular disease, and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, vascular access products,
angiographic products and accessories, drainage products, thrombolytic products and venous products. For more information, visit www.angiodynamics.com.
Safe Harbor
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All
statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of
management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," “projects”, "optimistic," or variations of such words and similar
expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from
AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its
existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to
effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical
trials, overall economic conditions, the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability
claims, changes
in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital
market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate acquired businesses, as
well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2020. AngioDynamics does not assume any obligation to publicly update or revise any
forward-looking statements for any reason.
In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the
surgical ablation of soft tissue and is similarly approved for commercialization in Canada, the European Union, and Australia. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.
|
ANGIODYNAMICS, INC. AND SUBSIDIARIES
|
|
CONSOLIDATED INCOME STATEMENTS
|
|
(in thousands, except per share data)
|
|
Three Months Ended
|
Twelve Months Ended
|
|||||||||||||||
|
May 31, 2021
|
May 31, 2020
|
May 31, 2021
|
May 31, 2020
|
|||||||||||||
|
(unaudited)
|
(unaudited)
|
(audited)
|
||||||||||||||
|
Net sales
|
$
|
76,842
|
$
|
58,332
|
$
|
291,010
|
$
|
264,157
|
||||||||
|
Cost of sales (exclusive of intangible amortization)
|
34,522
|
28,120
|
134,222
|
113,885
|
||||||||||||
|
Gross profit
|
42,320
|
30,212
|
156,788
|
150,272
|
||||||||||||
|
% of net sales
|
55.1
|
%
|
51.8
|
%
|
53.9
|
%
|
56.9
|
%
|
||||||||
|
Operating expenses
|
||||||||||||||||
|
Research and development
|
9,104
|
7,232
|
36,390
|
29,682
|
||||||||||||
|
Sales and marketing
|
23,820
|
18,207
|
81,306
|
78,634
|
||||||||||||
|
General and administrative
|
9,131
|
8,221
|
35,918
|
37,872
|
||||||||||||
|
Amortization of intangibles
|
4,298
|
4,704
|
18,136
|
18,121
|
||||||||||||
|
Goodwill impairment
|
—
|
158,578
|
—
|
158,578
|
||||||||||||
|
Change in fair value of contingent consideration
|
379
|
(11,647
|
)
|
89
|
(11,531
|
)
|
||||||||||
|
Acquisition, restructuring and other items, net
|
17,175
|
1,528
|
20,232
|
6,014
|
||||||||||||
|
Total operating expenses
|
63,907
|
186,823
|
192,071
|
317,370
|
||||||||||||
|
Operating loss
|
(21,587
|
)
|
(156,611
|
)
|
(35,283
|
)
|
(167,098
|
)
|
||||||||
|
Interest expense, net
|
(185
|
)
|
(235
|
)
|
(861
|
)
|
(907
|
)
|
||||||||
|
Other income (expense), net
|
(167
|
)
|
(63
|
)
|
92
|
(130
|
)
|
|||||||||
|
Total other expense, net
|
(352
|
)
|
(298
|
)
|
(769
|
)
|
(1,037
|
)
|
||||||||
|
Loss before income tax benefit
|
(21,939
|
)
|
(156,909
|
)
|
(36,052
|
)
|
(168,135
|
)
|
||||||||
|
Income tax expense (benefit)
|
(2,471
|
)
|
158
|
(4,504
|
)
|
(1,348
|
)
|
|||||||||
|
Net loss
|
$
|
(19,468
|
)
|
$
|
(157,067
|
)
|
$
|
(31,548
|
)
|
$
|
(166,787
|
)
|
||||
|
Loss per share
|
||||||||||||||||
|
Basic
|
$
|
(0.51
|
)
|
$
|
(4.13
|
)
|
$
|
(0.82
|
)
|
$
|
(4.39
|
)
|
||||
|
Diluted
|
$
|
(0.51
|
)
|
$
|
(4.13
|
)
|
$
|
(0.82
|
)
|
$
|
(4.39
|
)
|
||||
|
Weighted average shares outstanding
|
||||||||||||||||
|
Basic
|
38,525
|
38,072
|
38,342
|
37,961
|
||||||||||||
|
Diluted
|
38,525
|
38,072
|
38,342
|
37,961
|
||||||||||||
|
ANGIODYNAMICS, INC. AND SUBSIDIARIES
|
|
GAAP TO NON-GAAP RECONCILIATION
|
|
(in thousands, except per share data)
|
|
Reconciliation of Net Loss to non-GAAP Adjusted Net Income (Loss):
|
|
Three Months Ended
|
Twelve Months Ended
|
|||||||||||||||
|
May 31, 2021
|
May 31, 2020
|
May 31, 2021
|
May 31, 2020
|
|||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||
|
Net loss
|
$
|
(19,468
|
)
|
$
|
(157,067
|
)
|
$
|
(31,548
|
)
|
$
|
(166,787
|
)
|
||||
|
Amortization of intangibles
|
4,298
|
4,704
|
18,136
|
18,121
|
||||||||||||
|
Goodwill impairment
|
—
|
158,578
|
—
|
158,578
|
||||||||||||
|
Change in fair value of contingent consideration
|
379
|
(11,647
|
)
|
89
|
(11,531
|
)
|
||||||||||
|
Dosimetry inventory write-off (1)
|
—
|
958
|
—
|
958
|
||||||||||||
|
Acquisition, restructuring and other items, net (2)
|
17,175
|
1,528
|
20,232
|
6,014
|
||||||||||||
|
Write-off of deferred financing fees (3)
|
—
|
—
|
—
|
593
|
||||||||||||
|
Tax effect of non-GAAP items (4)
|
(2,451
|
)
|
799
|
(5,057
|
)
|
(2,406
|
)
|
|||||||||
|
Adjusted net income (loss)
|
$
|
(67
|
)
|
$
|
(2,147
|
)
|
$
|
1,852
|
$
|
3,540
|
||||||
|
Reconciliation of Diluted Loss Per Share to non-GAAP Adjusted Diluted Earnings (Loss) Per Share:
|
|||||||
|
Three Months Ended
|
Twelve Months Ended
|
|||||||||||||||
|
May 31, 2021
|
May 31, 2020
|
May 31, 2021
|
May 31, 2020
|
|||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||
|
Diluted loss per share
|
$
|
(0.51
|
)
|
$
|
(4.13
|
)
|
$
|
(0.82
|
)
|
$
|
(4.39
|
)
|
||||
|
Amortization of intangibles
|
0.11
|
0.12
|
0.47
|
0.48
|
||||||||||||
|
Goodwill impairment
|
—
|
4.17
|
—
|
4.16
|
||||||||||||
|
Change in fair value of contingent consideration
|
0.01
|
(0.31
|
)
|
—
|
(0.30
|
)
|
||||||||||
|
Dosimetry inventory write-off (1)
|
—
|
0.03
|
—
|
0.03
|
||||||||||||
|
Acquisition, restructuring and other items, net (2)
|
0.45
|
0.04
|
0.53
|
0.16
|
||||||||||||
|
Write-off of deferred financing fees (3)
|
—
|
—
|
—
|
0.02
|
||||||||||||
|
Tax effect of non-GAAP items (4)
|
(0.06
|
)
|
0.02
|
(0.13
|
)
|
(0.07
|
)
|
|||||||||
|
Adjusted diluted earnings (loss) per share
|
$
|
—
|
$
|
(0.06
|
)
|
$
|
0.05
|
$
|
0.09
|
|||||||
|
Adjusted diluted sharecount (5)
|
38,525
|
38,072
|
39,110
|
38,105
|
||||||||||||
|
(1) Write-off of raw materials and existing dosimetry inventory associated with OARtrac that was purchased pursuant to the Company’s
acquisition of RadiaDyne. These inventory items were deemed unmarketable absent subsequent design and development activities.
|
||||||||||||||||
|
(2) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and
write-offs, certain litigation, and other items. Fiscal year 2021 results include a $14.0 million write-off of OARtrac intangible assets.
|
||||||||||||||||
|
(3) Deferred financing fees related to the old credit agreement were written off during the first quarter of fiscal year 2020.
|
||||||||||||||||
|
(4) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's
U.S. deferred tax assets and an effective tax rate of 23% for the periods ended May 31, 2021 and May 31, 2020.
|
||||||||||||||||
|
(5) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss.
|
||||||||||||||||
|
ANGIODYNAMICS, INC. AND SUBSIDIARIES
|
|
GAAP TO NON-GAAP RECONCILIATION (Continued)
|
|
(in thousands, except per share data)
|
|
Reconciliation of Net Loss to Adjusted EBITDA:
|
|||||||
|
Three Months Ended
|
Twelve Months Ended
|
|||||||||||||||
|
May 31, 2021
|
May 31, 2020
|
May 31, 2021
|
May 31, 2020
|
|||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||
|
Net loss
|
$
|
(19,468
|
)
|
$
|
(157,067
|
)
|
$
|
(31,548
|
)
|
$
|
(166,787
|
)
|
||||
|
Income tax expense (benefit)
|
(2,471
|
)
|
158
|
(4,504
|
)
|
(1,348
|
)
|
|||||||||
|
Interest expense, net
|
185
|
235
|
861
|
907
|
||||||||||||
|
Depreciation and amortization
|
6,485
|
6,216
|
25,761
|
23,650
|
||||||||||||
|
Goodwill impairment
|
—
|
158,578
|
—
|
158,578
|
||||||||||||
|
Change in fair value of contingent consideration
|
379
|
(11,647
|
)
|
89
|
(11,531
|
)
|
||||||||||
|
Stock based compensation
|
2,227
|
1,594
|
8,625
|
7,592
|
||||||||||||
|
Dosimetry inventory write-off (1)
|
—
|
958
|
—
|
958
|
||||||||||||
|
Acquisition, restructuring and other items, net (2)
|
17,175
|
1,528
|
20,232
|
6,014
|
||||||||||||
|
Adjusted EBITDA
|
$
|
4,512
|
$
|
553
|
$
|
19,516
|
$
|
18,033
|
||||||||
|
Per diluted share:
|
||||||||||||||||
|
Adjusted EBITDA
|
$
|
0.12
|
$
|
0.01
|
$
|
0.50
|
$
|
0.47
|
||||||||
|
(1) Write-off of raw materials and existing dosimetry inventory associated with OARtrac that was purchased pursuant to the Company’s
acquisition of RadiaDyne. These inventory items were deemed unmarketable absent subsequent design and development activities.
|
|
(2) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and
write-offs, certain litigation, and other items. Fiscal year 2021 results include a $14.0 million write-off of OARtrac intangible assets.
|
|
ANGIODYNAMICS, INC. AND SUBSIDIARIES
|
|
NET SALES BY PRODUCT CATEGORY AND BY GEOGRAPHY
|
|
(in thousands)
|
| Three Months Ended |
Twelve Months Ended |
|||||||||||||||||||||||||||||||||||||||
|
May 31,
2021
|
May 31,
2020
|
%
Growth
|
Currency Impact |
Constant Currency Growth |
May 31, 2021 |
May 31, 2020 |
%
Growth
|
|
Currency Impact |
Constant Currency Growth |
||||||||||||||||||||||||||||||
| (unaudited) |
(unaudited) |
|||||||||||||||||||||||||||||||||||||||
| Net Sales by Product Category | ||||||||||||||||||||||||||||||||||||||||
|
Endovascular Therapies
|
$
|
38,071
|
$
|
22,090
|
72.3
|
%
|
$
|
135,079
|
$
|
112,706
|
19.9
|
%
|
||||||||||||||||||||||||||||
|
Vascular Access
|
24,462
|
23,714
|
3.2
|
%
|
101,310
|
94,299
|
7.4
|
%
|
||||||||||||||||||||||||||||||||
|
Oncology
|
14,309
|
12,528
|
14.2
|
%
|
54,621
|
57,152
|
(4.4
|
)%
|
||||||||||||||||||||||||||||||||
|
$
|
76,842
|
$
|
58,332
|
31.7
|
%
|
(0.8
|
)%
|
30.9
|
%
|
$
|
291,010
|
$
|
264,157
|
10.2
|
%
|
(0.4
|
)%
|
9.8
|
%
|
|||||||||||||||||||||
|
Net Sales by Geography
|
||||||||||||||||||||||||||||||||||||||||
|
United States
|
$
|
63,597
|
$
|
44,599
|
42.6
|
%
|
0.0
|
%
|
42.6
|
%
|
$
|
237,043
|
$
|
207,980
|
14.0
|
%
|
0.0
|
%
|
14.0
|
%
|
||||||||||||||||||||
|
International
|
13,245
|
13,733
|
(3.6
|
)%
|
(3.6
|
)%
|
(7.2
|
)%
|
53,967
|
56,177
|
(3.9
|
)%
|
(1.9
|
)%
|
(5.8
|
)%
|
||||||||||||||||||||||||
|
$
|
76,842
|
$
|
58,332
|
31.7
|
%
|
(0.8
|
)%
|
30.9
|
%
|
$
|
291,010
|
$
|
264,157
|
10.2
|
%
|
(0.4
|
)%
|
9.8
|
%
|
|||||||||||||||||||||
|
ANGIODYNAMICS, INC. AND SUBSIDIARIES
|
|
CONSOLIDATED BALANCE SHEETS
|
|
(in thousands)
|
|
May 31, 2021
|
May 31, 2020
|
|||||||
|
(unaudited)
|
(audited)
|
|||||||
|
Assets
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$
|
48,161
|
$
|
54,435
|
||||
|
Accounts receivable, net
|
35,405
|
31,263
|
||||||
|
Inventories
|
48,614
|
59,905
|
||||||
|
Prepaid expenses and other
|
8,699
|
7,310
|
||||||
|
Total current assets
|
140,879
|
152,913
|
||||||
|
Property, plant and equipment, net
|
37,073
|
28,312
|
||||||
|
Other assets
|
13,193
|
15,338
|
||||||
|
Intangible assets, net
|
168,977
|
197,136
|
||||||
|
Goodwill
|
201,316
|
200,515
|
||||||
|
Total assets
|
$
|
561,438
|
$
|
594,214
|
||||
|
Liabilities and stockholders' equity
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$
|
19,630
|
$
|
19,096
|
||||
|
Accrued liabilities
|
35,459
|
29,380
|
||||||
|
Current portion of contingent consideration
|
—
|
836
|
||||||
|
Other current liabilities
|
2,495
|
2,133
|
||||||
|
Total current liabilities
|
57,584
|
51,445
|
||||||
|
Long-term debt, net of current portion
|
20,000
|
40,000
|
||||||
|
Deferred income taxes
|
19,955
|
24,057
|
||||||
|
Contingent consideration, net of current portion
|
15,741
|
14,811
|
||||||
|
Other long-term liabilities
|
8,701
|
9,029
|
||||||
|
Total liabilities
|
121,981
|
139,342
|
||||||
|
Stockholders' equity
|
439,457
|
454,872
|
||||||
|
Total Liabilities and Stockholders' Equity
|
$
|
561,438
|
$
|
594,214
|
||||
|
ANGIODYNAMICS, INC. AND SUBSIDIARIES
|
|
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
|
(in thousands)
|
|
Three Months Ended
|
Twelve Months Ended
|
|||||||||||||||
|
May 31, 2021
|
May 31, 2020
|
May 31, 2021
|
May 31, 2020
|
|||||||||||||
|
(unaudited)
|
(unaudited)
|
(audited)
|
||||||||||||||
|
Cash flows from operating activities:
|
||||||||||||||||
|
Net loss
|
$
|
(19,468
|
)
|
$
|
(157,067
|
)
|
$
|
(31,548
|
)
|
$
|
(166,787
|
)
|
||||
|
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
|
||||||||||||||||
|
Depreciation and amortization
|
6,524
|
6,255
|
25,916
|
23,805
|
||||||||||||
|
Non-cash lease expense
|
596
|
503
|
2,456
|
2,070
|
||||||||||||
|
Goodwill impairment
|
—
|
158,578
|
—
|
158,578
|
||||||||||||
|
Stock based compensation
|
2,227
|
1,594
|
8,625
|
7,592
|
||||||||||||
|
Change in fair value of contingent consideration
|
379
|
(11,647
|
)
|
89
|
(11,531
|
)
|
||||||||||
|
Deferred income tax provision
|
(2,618
|
)
|
38
|
(4,805
|
)
|
(1,568
|
)
|
|||||||||
|
Change in accounts receivable allowances
|
176
|
243
|
207
|
429
|
||||||||||||
|
Asset impairments and disposals
|
14,038
|
333
|
14,228
|
1,321
|
||||||||||||
|
Other
|
2
|
16
|
(147
|
)
|
86
|
|||||||||||
|
Changes in operating assets and liabilities, net of acquisitions:
|
||||||||||||||||
|
Accounts receivable
|
(2,339
|
)
|
4,084
|
(4,162
|
)
|
11,918
|
||||||||||
|
Inventories
|
420
|
(4,809
|
)
|
11,539
|
(18,845
|
)
|
||||||||||
|
Prepaid expenses and other
|
5,640
|
3,223
|
(3,181
|
)
|
(6,155
|
)
|
||||||||||
|
Accounts payable, accrued and other liabilities
|
6,622
|
2,536
|
4,876
|
(15,467
|
)
|
|||||||||||
|
Net cash provided by (used in) operating activities
|
12,199
|
3,880
|
24,093
|
(14,554
|
)
|
|||||||||||
|
Cash flows from investing activities:
|
||||||||||||||||
|
Additions to property, plant and equipment
|
(9,144
|
)
|
(1,479
|
)
|
(13,711
|
)
|
(7,235
|
)
|
||||||||
|
Acquisition of intangibles
|
—
|
—
|
—
|
(350
|
)
|
|||||||||||
|
Cash paid in acquisition
|
—
|
—
|
—
|
(55,760
|
)
|
|||||||||||
|
Net cash used in investing activities
|
(9,144
|
)
|
(1,479
|
)
|
(13,711
|
)
|
(63,345
|
)
|
||||||||
|
Cash flows from financing activities:
|
||||||||||||||||
|
Repayment of long-term debt
|
(10,000
|
)
|
—
|
(20,000
|
)
|
(132,500
|
)
|
|||||||||
|
Proceeds from borrowings on long-term debt
|
—
|
25,000
|
—
|
40,000
|
||||||||||||
|
Deferred financing costs on long-term debt
|
—
|
—
|
—
|
(775
|
)
|
|||||||||||
|
Payment of acquisition related contingent consideration
|
—
|
—
|
—
|
(1,208
|
)
|
|||||||||||
|
Proceeds (outlays) from exercise of stock options and employee stock purchase plan
|
555
|
(53
|
)
|
3,014
|
(759
|
)
|
||||||||||
|
Net cash provided by (used in) financing activities
|
(9,445
|
)
|
24,947
|
(16,986
|
)
|
(95,242
|
)
|
|||||||||
|
Effect of exchange rate changes on cash and cash equivalents
|
82
|
(73
|
)
|
330
|
(65
|
)
|
||||||||||
|
Increase (decrease) in cash and cash equivalents
|
(6,308
|
)
|
27,275
|
(6,274
|
)
|
(173,206
|
)
|
|||||||||
|
Cash and cash equivalents at beginning of period
|
54,469
|
27,160
|
54,435
|
227,641
|
||||||||||||
|
Cash and cash equivalents at end of period
|
$
|
48,161
|
$
|
54,435
|
$
|
48,161
|
$
|
54,435
|
||||||||
|
ANGIODYNAMICS, INC. AND SUBSIDIARIES
|
|
GAAP TO NON-GAAP RECONCILIATION
|
|
(in thousands)
|
|
Reconciliation of Free Cash Flows:
|
||||||||||||||||
|
Three Months Ended
|
Twelve Months Ended
|
|||||||||||||||
|
May 31, 2021
|
May 31, 2020
|
May 31, 2021
|
May 31, 2020
|
|||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||
|
Net cash (used in) provided by operating activities
|
$
|
12,199
|
$
|
3,880
|
$
|
24,093
|
$
|
(14,554
|
)
|
|||||||
|
Additions to property, plant and equipment
|
(9,144
|
)
|
(1,479
|
)
|
(13,711
|
)
|
(7,235
|
)
|
||||||||
|
Free Cash Flow
|
$
|
3,055
|
$
|
2,401
|
$
|
10,382
|
$
|
(21,789
|
)
|
|||||||
Exhibit 99.2
ANGIODYNAMICS Fourth Quarter 2021 Earnings PresentationJuly 13, 2021 1
2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets,
projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,”
“anticipates,” “plans,” “projects,” “believes,” “seeks,” “estimates,” “optimistic,” or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics’ expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics
include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics’
technology or assertions that AngioDynamics’ technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or
other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, challenges with respect to
third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic
initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition,
the ability of AngioDynamics to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2020.
AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in
the surgical ablation of soft tissue, and is similarly approved for commercialization in Canada, the European Union and Australia. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.Notice
Regarding Non-GAAP Financial MeasuresManagement uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics’ business over time. Investors
should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this presentation, AngioDynamics has reported adjusted EBITDA (income before
interest, taxes, depreciation and amortization and stock-based compensation); adjusted net income and adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management
believes that these measures provide investors with useful information in comparing AngioDynamics’ performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance
of AngioDynamics’ underlying business. Management encourages investors to review AngioDynamics’ financial results prepared in accordance with GAAP to understand AngioDynamics’ performance taking into account all relevant factors, including
those that may only occur from time to time but have a material impact on AngioDynamics’ financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.
Corporate Developments – Q4 Highlights 3 108% growth in AngioVac YOY$4.6 million in
Auryon sales NanoKnife disposable growth: US 69% YOY; worldwide growth of 42% YOY YOY comparisons are significantly impacted by the COVID-19 global pandemicProcedural volumes continued to rebound in Q4 AngioVac cases continued their sequential
quarterly growth Continued focused investment in our 3 key technology platforms: Auryon, AngioVac & NanoKnife NanoKnife DIRECT study: 26 active sitesEncouraged by the overall execution of the study in the current environment Revised
FY2021 Guidance Reduced debt outstanding under the revolver to $20.0 million as of May 31, 2021 Completed enrollment of PATHFINDER 1 pilot registry Shifting our focus to the pivotal study phase Received FDA clearance for the AlphaVac
Mechanical Thrombectomy System subsequent to quarter endReceived approval for NanoKnife prostate IDE (PRESERVE) subsequent to quarter end 3 FY22 Guidance Revenue Adjusted EPS $305 - $310 million $0.00 - $0.05 Gross Margin ~55% $14.0
million write-off of the OARtrac intangible assets
Fourth Quarter and FY2021 Highlights $ in thousands (except per share data) Q4 FY2021 Q4 FY2020 YOY
Change Revenue $76,842 $58,332 31.7% Gross Margin 55.1% 51.8% 330 bps Net Loss ($19,468) ($157,067) $137,599 GAAP EPS ($0.51) ($4.13) $3.62 Adjusted EPS $0.00 ($0.06) $0.06 Adjusted EBITDA $4,512 $553 $3,959 Financial
Performance Endovascular Therapies (formerly VIT) Q4 FY2021 FY2021 AngioVac® 108% 47% Auryon NA* NA* Thrombolytic (36%) (11%) Core Peripheral 47% 9% Venous Insufficiency 85% 0% Product Family Sales Growth Over Prior Year
Periods Vascular Access Q4 FY2021 FY2021 Midlines (2%) 28% C3 110% NA** PICCs (10%) 8% Ports 26% 5% Dialysis (3%) 1% Oncology Q4 FY2021 FY2021 NanoKnife® Capital (77%) (48%) NanoKnife® Disposables 42% 13% Solero®
Microwave 38% 11% BioSentry 93% 38% Alatus and IsoLoc Balloons 6% (18%) RadioFrequency Ablation (10%) (21%) * The Auryon full market launch took place in the second quarter of fiscal year 2021.** The C3 Wave acquisition took place
in December 2019. 4
Fourth Quarter and FY2021 Highlights Sales Growth Over Prior Year Periods – Additional Detail Med
Tech Q4 FY2021 FY2021 Auryon NA** NA** Mechanical Thrombectomy* 62% 32% NanoKnife® Disposables 42% 13% NanoKnife® Capital (77%) (48%) Med Device Q4 FY2021 FY2021 Solero® Microwave 38% 11% BioSentry 93% 38% Core
Peripheral 47% 9% Venous Insufficiency 85% 0% Alatus and IsoLoc Balloons 6% (18%) RadioFrequency Ablation (10%) (21%) Midlines (2%) 28% C3 110% NA*** PICCs (10%) 8% Ports 26% 5% Dialysis (3%) 1% * Mechanical
Thrombectomy comprises AngioVac and Thrombolytics.** The Auryon full market launch took place in the second quarter of fiscal year 2021.*** The C3 Wave acquisition took place in December 2019. 5
Fourth Quarter and FY2021 Results (unaudited) $ in thousands (except per share data) Q4 FY2021 Q4
FY2020 Change FY2021 FY2020 Change Revenue Endovascular Therapies (formerly VIT) Vascular Access Oncology United States
International $76,842$38,071$24,462$14,309$63,597$13,245 $58,332$22,090$23,714$12,528$44,599$13,733 31.7%72.3%3.2%14.2%42.6%(3.6%) $291,010$135,079$101,310$54,621$237,043$53,967 $264,157$112,706$94,299$57,152$207,980$56,177 10.2%19.9%7.4%(4.4%)14.0%(3.9%) Net
Loss*Non-GAAP Adjusted Net Income (Loss) ($19,468)($67) ($157,067)($2,147) $137,599$2,080 ($31,548)$1,852 ($166,787)$3,540 $135,239($1,688) GAAP EPS*Non-GAAP Adjusted
EPS ($0.51)$0.00 ($4.13)($0.06) $3.62$0.06 ($0.82)$0.05 ($4.39)$0.09 $3.57($0.04) Gross Margin 55.1% 51.8% 330 bps 53.9% 56.9% (300 bps) Adjusted EBITDA $4,512 $553 $3,959 $19,516 $18,033 $1,483 $ in thousands Q4
FY2021 Q4 FY2020 Change Cash $48,161 $54,435 ($6,274) Debt $20,000 $40,000 ($20,000) Net Cash $28,161 $14,435 $13,726 6 * Current year Net Loss and GAAP EPS include a $14.0 million write-off of OARtrac intangible assets and
prior year Net Loss and GAAP EPS include a $158.6 million goodwill impairment charge.
GAAP to Non-GAAP Reconciliation 7
Reconciliation of GAAP to Non-GAAP Net Income and EPS Reconciliation of Net Loss to Adjusted
EBITDA Write-off of raw materials and existing dosimetry inventory associated with OARtrac that was purchased pursuant to the Company’s acquisition of RadiaDyne. These inventory items were deemed unmarketable absent subsequent design and
development activities.Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items. Fiscal year 2021 results include a $14.0
million write-off of OARtrac intangible assets.Deferred financing fees related to the old credit agreement were written off during the second quarter of fiscal year 2020.Adjustment to reflect the income tax provision on a non-GAAP basis has
been calculated assuming no valuation allowance on the Company's U.S. deferred tax assets and an effective tax rate of 23% for the periods ended May 31, 2021 and May 31, 2020.Diluted shares may differ for non-GAAP measures as compared to GAAP
due to a GAAP loss. 8 Write-off of raw materials and existing dosimetry inventory associated with OARtrac that was purchased pursuant to the Company’s acquisition of RadiaDyne. These inventory items were deemed unmarketable absent subsequent
design and development activities.Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items. Fiscal year 2021 results include
a $14.0 million write-off of OARtrac intangible assets. (in thousands, except per share data) (in thousands)
9